| Name | Title | Contact Details |
|---|
EG GILERO is the merger of trusted companies in the medical device industry whose roots go back decades. GILERO Biomedical, Medacys, InField Medical and the medical businesses of eNNOVEA and ValTech Holdings have been brought together by EGI, Inc. to create one vertically integrated resource for the medical device industry. EG GILERO is your single-source, trusted partner for design, development and manufacturing within the medical devices, drug delivery, and primary pharmaceutical packaging markets. With operations in the United States and Asia, EG GILERO is strategically positioned to provide the value added services our clients require in a competitive, ever-changing global marketplace. Together, we will accelerate your device timelines from concept to commercialization.
Biomerica is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Young Dental is a Earth City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our vision is to free diabetics from the painful finger prick and throughout this leverage for our shareholders the significant market potential that such a non-invasive glucose monitor could achieve.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.